Investors, pharma, advocates cite “market failure” in developing new treatments

WASHINGTON — Large pharmaceutical companies, investors, and other funders must increase investments to address antimicrobial resistance (AMR), and must do so now, experts and industry insiders said here this week.

However, most expressed skepticism that this will happen.

Speaking at the annual World AMR Congress, Greg Frank, PhD, director of global public policy for Merck, noted that “there’s very big challenges” in raising funds to address AMR…

Read the full article here.